



# The many faces of Crohn's disease. And one face of its treatment.

Salazopyrin has long been established as standard treatment for ulcerative colitis and there is now further evidence to support its use as a first-line therapy for active Crohn's disease.

Now a double-blind study<sup>(1)</sup> has shown that 62% of Salazopyrin-treated patients responded favourably (at least 25% reduction in Crohn's disease activity) compared with only 8% of patients given placebo.

This supports the findings of a major study<sup>(2)</sup> in the USA, the NCCDS\* involving some 569 patients, which compared Salazopyrin with azathioprine and prednisone both as short-term treatments to suppress acute disease and as long-term prophylactics against relapse. For active disease both Salazopyrin and prednisone were superior to placebo and in patients not previously treated with drugs or surgery, only Salazopyrin was superior to placebo.

Salazopyrin was also by far the least toxic of the drugs tested, which "...together with evidence of its usefulness, particularly for control of disease involving the colon, indicates sulphasalazine as the drug of choice for initial therapy of such patients."

National Cooperative Crohn's Disease Study.

## SALAZOPYRIN sulphasalazine

**YOUR BEST STARTING POINT IN ACTIVE  
CROHN'S DISEASE.**

### Prescribing Information Dosage and Administration

**Plain or EN Tablets:** In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks steroids should also be given. After 2-3 weeks the dose may gradually be reduced to the maintenance level of 3-4 tablets daily which should be given indefinitely. **Suppositories:** Two inserted morning and night, the dose being gradually reduced after 3 weeks as improvement occurs.


**Enema:** One enema should be given daily preferably at bed time. This preparation contains an adult dose of Salazopyrin. Patient instructions are enclosed in each box. **Children:** Reduce the adult dose on the basis of body weight.

### Contra-Indications, warnings etc.

**Contra-Indications:** Contra-indicated in sensitivity to salicylates and sulphonamides. Infants under 2 years. **Enema only:** Sensitivity to parabens

**Adverse Reactions:** Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose. Use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued. Rarely the following adverse reactions have been reported.

**Haematological:** e.g. Heinz body anaemia, haemolytic anaemia, leucopenia, agranulocytosis and aplastic anaemia.  
**Hypersensitivity:** e.g. Rash, fever  
**Gastrointestinal:** e.g. Impaired folate uptake, stomatitis, C.N.S., e.g. Headache, peripheral neuropathy.  
**Fertility:** Reversible oligospermia  
**Renal:** e.g. Proteinuria, crystalluria  
Also: Stevens-Johnson syndrome and lung complications e.g. Fibrosing alveolitis



### Precautions:

Care in cases of porphyria, allergic, renal or hepatic disease, glucose 6-PD deficiency. Blood checks should be made initially and periodically.

### Pregnancy and Lactation:

While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or icteric hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.

### Packages & Prices:

Plain Tablets (0.5g): 100 & 500. £5.85 for 100  
EN Tablets (0.5g): 100 & 500. £7.60 for 100  
Suppositories (0.5g): 10 & 50. £2.35 for 10  
Enemas (3.0g): 7. £9.80 for 7

### Product Licence Numbers:

Plain Tablets 0009/5006 EN Tablets 0009/5007  
Suppositories 0009/5008 Enema 0009/0023  
1) Gut (1981) 22: 404-409  
2) Gastroenterology (1979) 77: 847 et seq.



**Pharmacia**

Salazopyrin (regd) sulphasalazine, is a product of Pharmacia (Great Britain) Ltd, Prince Regent Rd, Hounslow, Middlesex TW3 1NE. Tel. 01-572 7321. Further information is available on request from the Company.

PRESCRIBING INFORMATION: DOSAGE AND ADMINISTRATION: ADULTS: TABLETS, 150 mg TWICE DAILY FOR FOUR WEEKS FOR DUODENAL ULCER AND BENIGN GASTRIC ULCER. PATIENTS WITH A HISTORY OF RECURRENT ULCER MAY HAVE AN EXTENDED COURSE OF ONE TABLET DAILY. FOR REFLUX OESOPHAGITIS THE RECOMMENDED COURSE IS ONE TABLET TWICE DAILY FOR UP TO EIGHT WEEKS. IN PATIENTS WITH VERY HIGH GASTRIC ACID SECRETION (EG ZOLLINGER-ELLISON SYNDROME) THE STARTING DOSE IS 150 mg THREE

**Glaxo**

7257

**Now Gastric acid**

MES DAILY AND THIS MAY BE INCREASED, AS NECESSARY, TO WITHIN THE RANGE 600  
0 900 mg PER DAY. INJECTION. ZANTAC MAY BE GIVEN AS A SLOW INTRAVENOUS INJECTION  
F 50 mg WHICH MAY BE REPEATED EVERY SIX TO EIGHT HOURS OR AS AN INTRAVENOUS  
FUSION AT A RATE OF 25 mg PER HOUR FOR TWO HOURS REPEATABLE AT SIX TO EIGHT  
OUR INTERVALS. **SIDE EFFECTS:** NO SERIOUS ADVERSE EFFECTS HAVE BEEN REPORTED.  
**PRECAUTIONS:** WHERE GASTRIC ULCER IS SUSPECTED, THE POSSIBILITY OF MALIGNANCY  
OULD BE EXCLUDED BEFORE THERAPY IS INSTITUTED. PATIENTS RECEIVING PROLONGED  
REATMENT SHOULD BE OBSERVED PERIODICALLY. DOSAGE SHOULD BE REDUCED IN THE

PRESENCE OF SEVERE RENAL IMPAIRMENT (SEE DATA SHEET). AS WITH ALL DRUGS, ZANTAC  
SHOULD BE USED DURING PREGNANCY AND NURSING ONLY IF STRICTLY NECESSARY. **CONTRA-  
INDICATIONS:** THERE ARE NO KNOWN CONTRA-INDICATIONS TO THE USE OF ZANTAC. **BASIC  
NHS COST** (EXCLUSIVE OF VAT) 60 TABLETS £27.43; BOX OF 5 x 5 ml AMPOULES £3.21. PRODUCT  
LICENCE NUMBERS 150 mg TABLETS 4/0279 50 mg/5 ml AMPOULES 4/0280. FURTHER  
INFORMATION ON ZANTAC (TRADE MARK) IS AVAILABLE FROM: GLAXO LABORATORIES  
LIMITED, GREENFORD, MIDDLESEX UB6 0HE.

Zantac is the new histamine H<sub>2</sub>-antagonist from Glaxo, developed to add important benefits to the treatment of acid peptic disease.

#### Highly effective

Zantac's molecular structure confers important advantages in terms of specificity and duration of action.

Primarily however, Zantac promotes rapid, effective ulcer healing with sustained pain relief, both day and night.

#### Simple dosage regimens

Zantac was specially developed for B.D. dosage. The recommended treatment course for duodenal ulcer and benign gastric ulcer, is one 150 mg tablet twice daily for four weeks.

For extended maintenance therapy, the dosage is just one tablet taken nightly.

In the management of reflux oesophagitis, one tablet twice daily for up to eight weeks, is recommended.

#### Highly specific action

Due to its innovative molecular structure, Zantac does not cause problems with endocrine or gonadal function, or adverse effects on the central nervous system, even in elderly patients.

Similarly, as Zantac does not interfere with liver enzyme function, there are no unwanted effects on the metabolism of drugs such as diazepam and warfarin which may be prescribed concomitantly.

Zantac injection ampoules are also available, containing 50 mg ranitidine in 5 ml for intravenous injection or infusion for use in acute cases where oral therapy is inappropriate.

has a new H<sub>2</sub> blocker to worry about.

# Zantac

RANITIDINE

# HEALING OF PEPTIC ULCER

"by restoring gastric  
physiology to normal"<sup>1</sup>

"Carbenoxolone . . . acts by restoring gastric physiology to normal in strengthening the mucosal barrier, rather than by creating a non-physiological situation of hypochlorhydria, such as antacids and H<sub>2</sub> receptor antagonists produce."<sup>1</sup>

1. XI Int. Cong. Gastroenterology,  
Hamburg, June 1980.

- Increased mucus production
- Reduced epithelial cell loss
- Reduced peptic secretion and activity




## BIOGASTRONE

carbenoxolone  
for gastric ulcer



## DUOGASTRONE

carbenoxolone  
for duodenal ulcer



Further information available from Winthrop Laboratories, Surbiton-upon-Thames, Surrey KT6 4PH. See prescribing data overleaf.

WINTHROP

# BIOGASTRONE

**carbenoxolone**  
for gastric ulcer

Carbenoxolone sodium BP 50 mg tablets.  
PL 0071/5902. Bottles of 100. Basic NHS cost: 1  
week's treatment £2.21 (21 tablets) - £4.42 (42  
tablets).

**Adult dose:** 2 tablets t.i.d. after meals for the first  
week then 1 tablet t.i.d. until ulcer is healed  
(usually 4-6 weeks).

# DUOGASTRONE

**carbenoxolone**  
for duodenal ulcer

Carbenoxolone sodium BP. 50 mg  
position-release capsules. Bottles of 28.  
PL 0071/5903. Basic NHS cost: 1 day's treatment  
(4 capsules) 85p.

**Adult dose:** 1 capsule swallowed whole and  
unbroken with liquid q.i.d., 15-30 minutes before  
meals. Patients may continue to take antacids  
but anticholinergic drugs should be  
discontinued. Treatment should continue for 6-12  
weeks.

**Safety factors: Biogastrone and  
Duogastrone**

**Contra-indications.** Severe cardiac, renal or  
hepatic failure. Patients on digitalis therapy,  
unless serum electrolyte levels are monitored  
weekly and measures taken to prevent the  
development of hypokalaemia.

**Precautions.** Special care should be exercised  
with patients pre-disposed to sodium and water  
retention, potassium loss and hypertension (e.g.  
the elderly and those with cardiac, renal or  
hepatic disease) since carbenoxolone can  
induce similar changes. Regular monitoring of  
weight and blood pressure, which should  
indicate such effects, is advisable for all patients.  
A thiazide diuretic should be administered if  
oedema or hypertension occurs.

(Spironolactone should not be used because it  
hinders the therapeutic action of  
carbenoxolone). Potassium loss should be  
corrected by the administration of oral  
supplements. No teratogenic effects have been  
reported with carbenoxolone sodium, but  
careful consideration should be given before  
prescribing Biogastrone, Duogastrone or  
Pyrogastrome for women who may become  
pregnant.

Biogastrone and Duogastrone are registered  
trade marks.

Made under licence from Biorex Laboratories,  
Brit. Pat. No. 1093286.

Further information available from Winthrop  
Laboratories, Surbiton-upon-Thames, Surrey  
KT6 4PH.

**WINTHROP**

## Gastrointestinal and Related Hormones

*The Proceedings of a Symposium organised by  
The Association of Clinical Pathologists*

*Edited by G. Walters and S. R. Bloom*

### CONTENTS

Editor's foreword ● The endocrine versatility  
of the gut: general and evolutionary aspects of  
the active peptides of the gastrointestinal  
tract ● Visualisation of the diffuse endocrine  
system ● Neurotensin ● Pathophysiology of  
gastrin and secretin ● The measurement of  
cholecystokinin ● Gastric inhibitory poly-  
peptide (GIP) ● The enteroinsular axis ●  
Pancreatic polypeptide ● Importance of the  
jejunal hormone motilin ● Gut glucagon-like  
immunoreactants (GLIs) and other enteric  
glucagon-like peptides ● Vasoactive intestinal  
peptide (VIP) ● Brain and gut peptides ●  
Gut hormones in gastrointestinal disease ●  
Clinical features and diagnosis of alimentary  
endocrine tumours ●

**Price: Inland £5.00;  
Abroad US\$12.50,  
including postage**

Payment must be enclosed with order or a surcharge of 50p  
will be made for rendering invoices and statements.

The Publisher, *Journal of Clinical Pathology*  
BMA House, Tavistock Square, London  
WC1H 9JR


# The Old Retainer



## Time to say Goodbye?

**Presentation** White odourless aerosol foam containing hydrocortisone acetate 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed in each pack). Satisfactory response usually occurs within

five to seven days. **Contra-indications and Warnings, etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulas. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative diseases because of their predisposition to perforation of




For many years the retention enema has been the best way to get topical steroid therapy into the rectum and distal colon to relieve inflammatory bowel disease. Thousands of colitis sufferers are familiar with its benefits – and also its drawbacks, mainly the sheer inconvenience and discomfort of administering it.

Now there is an alternative to the retention enema – another form of topical therapy, comparable in efficacy but far easier for the patient to use. **Colifoam**: a unique foam presentation of hydrocortisone which is easily administered using a simple plastic applicator.

## More acceptable than steroid enema

Clark\* reported on a clinical trial of Colifoam in 20 patients with inflammatory bowel disease. Proctitic symptoms were controlled in 17, and 11 out of 12 patients who had previously been treated with prednisolone enemas, found Colifoam "... easier and more convenient to use". Three of these patients found Colifoam the more effective treatment and the others thought there was no difference in efficacy between Colifoam and steroid enemas.

**N.B. A dose of Colifoam costs far less than a dose of a proprietary prednisolone retention enema.**



# Colifoam

hydrocortisone acetate foam

**a welcome alternative to the retention enema for distal inflammatory bowel disease**

the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Do not refrigerate, incinerate or puncture the aerosol can. Shake vigorously before use. Keep out of reach of children. **Package quantities** Aerosol canister containing 20g. (14 applications) plus a plastic applicator and illustrated leaflet. One applicatorful of 'Colifoam' provides a dose of approximately 90-110mg. of hydrocortisone acetate, similar to that used in a retention enema for

the treatment of ulcerative colitis, sigmoiditis and proctitis. **Product Licence No.** 0036/0021. **Basic NHS Cost** £7.58 \*Clark ML Practitioner 1977, 219-103

Further information is available on request.  
**Stafford-Miller Ltd.**, Professional Relations Division, Hatfield, Herts. AL10 0NZ



"I feel I'm so full I could burst!  
With this overblown stomach I'm cursed."  
The Doctor smiled sweetly,  
Then murmured discreetly,  
"Well, we'd better try Maxolon first."

For relief from  
heartburn and flatulence

# Maxolon

metoclopramide

## PRESCRIBING INFORMATION

### Indications

Dyspepsia, heartburn and flatulence associated with the following conditions e.g. Reflux oesophagitis, Gastritis, Hiatus hernia, Peptic ulcer.

### Adult Dosage (oral)

Adults 10mg  
1 tablet or 10ml syrup 3 times a day  
Young adults (15-20 years) 5-10mg  
½-1 tablet or 5-10ml syrup 3 times a day commencing at the lower dosage.  
Note: Total daily dosage of Maxolon, especially for children and young adults should not normally exceed 0.5mg/kg body weight.

### Side-effects and Precautions

There are no absolute contra-indications to the use of Maxolon.  
Various extra-pyramidal reactions to Maxolon, usually of the dystonic type, have been reported. The incidence of these reactions in children and young adults may be increased if daily dosages higher than 0.5mg/kg body weight are administered. The majority of reactions occur within 36 hours of starting treatment and the effects usually disappear within 24 hours of withdrawal of the drug. Should treatment of a reaction be required, an anticholinergic anti-Parkinsonian drug or a benzodiazepine may be used.

Since extra-pyramidal symptoms may occur with both Maxolon and phenothiazines, care should be exercised in the event of both drugs being prescribed concurrently.  
Raised serum prolactin levels have been observed during metoclopramide therapy; this effect is similar to that noted with many other compounds.  
Maxolon's action on the gastro-intestinal tract is antagonised by anticholinergics. Although animal tests in several mammalian species have shown no teratogenic effects, treatment with Maxolon is not advised during the first trimester of pregnancy.

Following operations such as pyloroplasty or gut anastomosis Maxolon therapy should be withheld for three or four days as vigorous muscular contractions may not help healing.

**Availability and NHS Prices**  
Tablets 10mg (£7.70 for 100)  
Syrup 5mg/5ml (£2.78 for 200ml).  
A paediatric liquid presentation and ampoules for injection are also available.  
Average daily cost of Maxolon tablets 23p.  
Prices correct at January 1981.

Further information is available on request to the company.



**Beecham Research Laboratories**

Brentford, England. A branch of Beecham Group Limited.  
Maxolon and the BRL logo are trade marks.

PL 0038/0095 0098 5040 5041.

BRL 4026



ETHICON

# Coated VICRYL\*

(polyglactin 910) sutures

*lies down smoothly*

*slides easily through*

*ties the*

*snugs down and holds*

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,  
Edinburgh EH11 4HE, Scotland.

PLR Nos 0508/0001 0508/0009

\*Trade Mark © ETHICON Ltd 1981

TECHNICAL DATA OVERLEAF

PRINTED IN GREAT BRITAIN

## TECHNICAL DATA

---

# STERILISED ABSORBABLE SYNTHETIC SUTURE COATED POLYGLACTIN 910 VICRYL \*

---

**Presentation** The basic VICRYL (Polyglactin 910) Suture is prepared from a copolymer of glycolide and lactide. The substances are derived respectively from glycolic and lactic acids. The empirical formula of the copolymer is  $(C_2H_2O_2)_m(C_3H_4O_2)_n$ .

Coated VICRYL (Polyglactin 910) Sutures are obtained by coating the braided suture material with a mixture composed of a copolymer of glycolide and lactide and an equal amount of calcium stearate. This coating does not affect the biological properties of the suture.

VICRYL (Polyglactin 910) Sutures are coloured by adding D & C Violet No 2 during polymerisation of the lactide and glycolide. Suture may also be manufactured in the undyed form.

These sutures are relatively inert, nonantigenic, nonpyrogenic and elicit only a mild tissue reaction during absorption.

**Action** Two important characteristics describe the in vivo behaviour of absorbable sutures. The first of these is tensile strength retention and the second absorption rate or loss of mass.

Subcutaneous tissue implantation studies of both VICRYL and Coated VICRYL Suture in rats show at two weeks post-implantation approximately 55% of its original tensile strength remains, while at three weeks approximately 20% of its original strength is retained.

Intramuscular implantation studies in rats show that the absorption of these sutures is minimal until about the 40th post-implantation day. Absorption is essentially complete between the 60th and 90th days.

**Uses** VICRYL and Coated VICRYL synthetic absorbable sutures are intended for use where an absorbable suture or ligature is indicated.

**Dosage and Administration**  
By implantation.

**Contraindications, Warnings, etc.**  
These sutures, being absorbable, should not be used where extended approximation of tissues under stress is required.

Sutures placed in skin and conjunctiva may cause localised irritation if left in place for longer than 10 days and should be removed as indicated.

The safety and effectiveness of VICRYL (Polyglactin 910) and Coated VICRYL Sutures in neural tissue and in cardiovascular tissue have not been established.

**Pharmaceutical Precautions**  
Do not re-sterilise.

**Legal Category P** Pharmacy medicine sold to surgeons and hospitals through surgical dealers.

**Package Quantities** Various lengths of material packaged in sealed aluminium foil sachets. This primary pack is contained in a peel-apart secondary pack. The unit of sales is 12 packs contained in a film wrapped drawer style carton.

**Adverse Reactions** No suture related adverse reactions were reported during clinical trials, although a number of minor reactions were classified as being of unknown cause.


Product Licence Nos PL 0508/0001  
PL 0508/0009

---

**ETHICON LTD.  
PO BOX 408, BANKHEAD AVE  
EDINBURGH EH11 4HE**

NEW  
PRODUCT

# A fresh approach to colonic relaxation



Conventional treatments for irritable bowel syndrome are often disappointing and have side effects.<sup>1</sup> New Colpermin provides an effective alternative treatment. Colpermin contains peppermint oil, a naturally-occurring carminative

which relaxes gastrointestinal muscle.<sup>2</sup> The active constituent is delivered as a liquid to the distal bowel in an enteric-coated capsule. This is a new concept made possible by advances in technology. In providing colonic relaxation,

Colpermin reduces intracolonic pressure, distension and pain. A controlled trial has demonstrated that Colpermin is "an effective and safe preparation for symptomatic treatment of the irritable bowel syndrome."<sup>1</sup>

# COLPERMIN<sup>TM</sup>

enteric coated peppermint oil

## Natural relief of colonic spasm

References 1. Rees WDW et al. *Br. Med. J.* 1979, 2, 835. 2. Evans BK. *PhD thesis (unpublished)*, University Hospital of Wales, 1980, 250-253. **Prescribing information:** **Presentation:** Enteric coated gelatine capsule. Each contains 0.2 ml standardised peppermint oil B.P. Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should not be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contraindications, Warnings etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424/0009. **Basic NHS Cost:** £10.00 per 100. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.

**Tillotts**  
LABORATORIES

# HIATUS HEARTBURN & OESOPHAGITIS



## PYROGASTRONE

carbenoxolone/magnesium trisilicate/dried aluminium hydroxide gel

### positive healing power

#### Prompt symptom relief

- Pyrogastrone quickly soothes the sensitive mucosa
- suppresses gastro-oesophageal reflux and protects against further acid/bile attack
- relieves heartburn, dyspepsia, dysphagia, regurgitation and retrosternal pain.

#### Complete oesophageal healing

- Pyrogastrone exerts a unique direct healing action on the oesophagus
- resolves mucosal inflammation, erosion and ulceration
- gives exceptionally high rates of endoscopic healing.

Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories, Brit. Pat. No. 1390683. Full information available from: - Winthrop Laboratories, Surbiton-upon-Thames, Surrey. **WINTHROP**

**Can De-Nol.....  
heal peptic ulcers as  
effectively as cimetidine  
with a lower relapse rate,  
an established safety  
record and at an  
economic price?**

**De-Nol**

**Tripotassium dicitrato bismuthate.**

**can.**

For further information contact:

**Brocades Great Britain Ltd**  
Brocades House, Pyrford Road West Byfleet  
Surrey KT14 6RA. Telephone: Byfleet 45536.

**References** Kang, J.Y. & Piper, D.W., *Aust. N.Z. Med.*, **10**, 111 (1980). Tanner et al, *Med. J. Aust.*, **1**, 1-2 (1979). Cowen et al, *Aust. N.Z. Med.*, **10**, 364-365 (1980). Martin et al, *Lancet*, 3rd January 1981, 7-10. Martin, D.F., *Mod. Med.*, April 1980.

De-Nol contains 120mg tri-potassium di-citrato bismuthate (as Bi<sub>2</sub>O<sub>3</sub>) per 5ml. For the treatment of gastric and duodenal ulcers. Oral administration, usually 5ml diluted with 15ml water four times a day on an empty stomach, half an hour before each of the three main meals and two hours after the last meal of the day. Contra-indicated theoretically in cases of severe renal insufficiency and in pregnancy. De-Nol may inhibit the efficacy of orally administered tetracyclines. Blackening of the stool usually occurs and darkening of the tongue has been reported. 28 day (560ml) treatment pack £10.19 P/L No. 0166/5024.



**Ease the spasm. Ease the mind.**

**LIBRAXIN**

clidinium bromide and chlordiazepoxide

**Clidinium bromide to calm the gut. Chlordiazepoxide to calm the mind.**

**Indications** For the control of hypersecretion, hypermotility and emotional factors associated with gastro-intestinal disorders, such as nervous dyspepsia, peptic ulcer, cardiospasm, pylorospasm, nervous or irritable colon.

**Dosage** 1 or 2 tablets three or four times daily. In elderly patients, it is recommended that the initial dose be 1 tablet twice daily.

**Contra-indications** Because of its anticholinergic effects, Libraxin should not be given to patients suffering from glaucoma or prostatic enlargement.

**Precautions** Patients should avoid alcohol while under treatment with Libraxin, since the individual

response cannot be foreseen. Patients' reactions (driving ability, operation of machinery, etc.) may be modified to a varying extent, depending on dosage and individual susceptibility. The established medical principle of prescribing medicaments in early pregnancy only when absolutely indicated should be observed.

**Side-effects** Side-effects are infrequent and are controlled by reduction of dosage. They include

drowsiness, muscle weakness, dryness of the mouth, blurring of vision, constipation and hesitancy of micturition.

**Presentation** Libraxin tablets containing 5mg chlordiazepoxide and 2.5mg clidinium bromide in packings of 100 and 500.

**Basic NHS Cost 1 tablet 3 times daily 7.4p/day ex 500 pack.**

**Licence Number** 0031/5024

**Licence Holder** Roche Products Limited, PO Box 8 Welwyn Garden City, Hertfordshire AL7 3AY  
Libraxin is a trade mark



ROCHE



# **G**ASTROENTEROLOGIE

Zeitschrift für

Organ der  
Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten,  
der Deutschen Gesellschaft für gastroenterologische Endoskopie und  
der Österreichischen Gesellschaft für Gastroenterologie

The highly specialized periodical  
for gastro-enterologists and internists;

Top level original papers  
relating to stomach, liver, pancreas and in-  
testines;

Comprehensive information  
on the advancements made in morphology,  
endoscopy and roentgenology;

Extensive bibliography;

Conference papers.

Subscription one year (twelve issues) DM 114.-. postage to be added:



**DEMETER VERLAG D-8032 GRÄFELFING**  
Tel.: (089) 85 20 33, Telex 05-24 068 delta d